Infections, Meningococcal
Conditions
Keywords
Safety, Reactogenicity, Immunogenicity, Meningococcal vaccine, Dose selection, Conjugate vaccine
Brief summary
The purpose of this study is to evaluate the immunogenicity, safety and reactogenicity of one dose of four different formulations of the MenACWY conjugate vaccine when given to healthy children aged 12 14 months and 3 5 years. The selection of the best formulation will be based on data obtained up to one month after the vaccine dose. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, September 2007.
Detailed description
The study will enrol subjects of 12 to 14 months of age and subjects of 3 to 5 years of age. Meningitec™ or Mencevax™ ACWY vaccine will serve as active control. The study will be conducted in two stages: The primary vaccination phase (Study Stage 1) of the study will include all subjects; the second (booster/persistence) phase of the study (Study Stage 2) will include subjects in the active control groups and in the group which was primed with the selected MenACWY formulation.
Interventions
One intramuscular dose during the primary vaccination
BIOLOGICALDTPa/Hib containing vaccine
One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age
BIOLOGICALMeningitec
One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age
BIOLOGICALMencevax ACWY
One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (group E) and subcutaneous administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (group C, group E)
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Months to 14 Months
Healthy volunteers
Yes
Inclusion criteria
* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol * A male or female between, and including, 12 and 14 months or 3 and 5 years of age at the time of the first vaccination * Written informed consent obtained from the parent or guardian of the subject. * Free of obvious health problems as established by medical history and clinical examination before entering into the study * Previously completed routine childhood vaccinations to the best of his/her parents'/guardians' knowledge. For pertussis vaccination, the children aged 12-14 months should have been vaccinated with an acellular pertussis vaccine.
Exclusion criteria
* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. * Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. * Planned administration/ administration of a vaccine not foreseen by the study protocol within one month of the first dose of vaccine and up to one month after administration of each study vaccine dose with the exception of oral polio vaccine. * Previous vaccination against meningococcal serogroup A, C, W-135 or Y disease. * Administration of a H. influenzae type b, diphtheria or tetanus vaccine within 3 months before the first dose of vaccine. * For subjects aged 12-14 months at enrolment, a DTPa/Hib containing booster vaccination, in the second year of life: these booster vaccines will be given at Visit 2. * History of meningococcal serogroup A, C, W-135 or Y disease. * Known exposure to meningococcal serogroup A, C, W-135 or Y disease within the previous year. * Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection. * A family history of congenital or hereditary immunodeficiency. * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. * Major congenital defects or serious chronic illness. * History of any neurologic disorders or seizures. * Acute disease at the time of enrolment. * Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of meningococcal rSBA responders, in all subjects | One month after the first vaccine dose |
Secondary
| Measure | Time frame |
|---|---|
| Anti-meningococcal polysaccharide concentrations | Prior to & 1 month after the 1st dose in all subjects and 15 months after priming in all subjects of groups C and E and one month after administration of the Mencevax ACWY booster dose in all subjects who received the booster dose |
| Anti-tetanus toxoid seropositivity and antibody concentrations | Prior to and one month after administration of the first vaccine dose, in all subjects |
| Meningococcal hSBA titers | Prior to & 1 month after the 1st dose and 15 months after priming in all subjects of groups C and E and one month after administration of the Mencevax ACWY booster dose in all subjects who received the booster dose |
| Meningococcal rSBA titres | Prior to & 1 month after the 1st dose in all subjects and 15 months after priming in all subjects of groups C and E and one month after administration of the Mencevax ACWY booster dose in all subjects who received the booster dose |
| Occurrence of unsolicited adverse events | During the 31-day follow-up period following the administration of each vaccine dose. |
| Occurrence of any serious adverse events | Throughout the study |
| Occurrence of local and general solicited adverse events | During the 8-day follow-up period following the administration of each vaccine dose. |
Countries
Austria, Germany
Outcome results
None listed